• Amgen announced positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren's disease, which has no FDA-approved treatments.
• Both dosing regimens reduced systemic disease activity versus placebo; the every-four-weeks regimen also improved patient-reported dryness.
• Serious adverse events and treatment discontinuations due to adverse events were balanced across treatment groups.
• Full results will be presented at the American College of Rheumatology Convergence 2026, following positive topline findings announced in September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611110800PR_NEWS_USPR_____LA94723) on November 11, 2026, and is solely responsible for the information contained therein.